Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus

References

• Ashwell S G, Amiel S A, Bilous R W, Dashora U, Heller S R, Hepburn D A, Shutler S D, Stephens J W, Home P D. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med 2006; 23: 285–292
   PubMed Web of Science ®Google Scholar
• Banting F, Best C H, Collip C P, Campbell W R, Fletcher A A. Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. Can Med Ass J 1922; 12: 141–146
   PubMedGoogle Scholar
• Becker R HA. Insulin glulisine complementing basal insulins: a review of structure and activity. Diab Technol & Ther 2007; 9: 109–121
   PubMed Web of Science ®Google Scholar
• Binder C, Lauritzen T, Faber O, Pramming S. Insulin Pharmacokinetics. Diabetes Care 1984; 7: 1888–1899
   Google Scholar
• Bliss M. The discovery of insulin. University of Chicago Press, Chicago 1982
   Google Scholar
• Bolli G B, Dimitriadis G D, Pehling G B, Baker B A, Haymond M W, Cryer P E, Gerich J E. Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus. N Engl J Med 1984; 160: 1706–1711
   Google Scholar
• Bolli G B. From Physiology of glucose counterregulation to prevention of hypoglycaemia in Type 1 diabetes mellitus. Diab Nutr Metab 1990; 4: 333–339
   Google Scholar
• Bolli G B, Di Marchi R, Park G, Pramming S, Koivisto V A. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999; 42: 1151–1167
   PubMed Web of Science ®Google Scholar
• Bolli G B. Treatment and prevention of hypoglycemia and its unawareness in Type 1 diabetes mellitus. Rev Endocr Metab Dis 2003; 4: 335–341
   PubMed Web of Science ®Google Scholar
• Bolli G B, Capani F, Home P D, Kerr D, Thomas R, Torlone E, Selam J L, Sola-Gazagnes A, Vitacolonna E. Comparison of a multiple daily injection regimen with once-daily insulin glargine basal insulin and meal time lispro, to continuous subcutaneous insulin infusion: a randomised, open, parallel study. (Abstract) Diabetes 2004; 53: A107
   Web of Science ®Google Scholar
• Bolli G B. Glucose Variability and Complications. Diabetes Care 2006; 29: 1707–1709
   PubMed Web of Science ®Google Scholar
• Brange J, Owens D R, Kang S, Vølund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923–954
   PubMed Web of Science ®Google Scholar
• Brownlee M, Hirsch I B. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006; 295: 1707–1708
   PubMed Web of Science ®Google Scholar
• Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, et al. In Type 1 diabetic patients with good metabolic control blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with glargine. Diabet Med 2008, in press
   Web of Science ®Google Scholar
• Ciofetta M, Lalli C, Del Sindaco P, Torlone E, Pampanelli S, Lepore M, Di Loreto C, Brunetti P, Bolli G B. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at meal time. Diabetes Care 1999; 22: 795–800
   PubMed Web of Science ®Google Scholar
• Colombel A, Krempf M, Kuchly-Anton B, Charbonnel B. Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections. Diabet. Med. 1999; 16: 169–124
   Google Scholar
• DeFronzo R A, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1982; 23: 163–169
   Web of Science ®Google Scholar
• Del Sindaco P, Ciofetta M, Lalli C, Perriello G, Pampanelli S, Torlone E, Brunetti P, Bolli G B. Use of the short-acting insulin analogue lispro in intensive treatment of IDDM: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet. Med. 1998; 15: 592–600
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986
   PubMed Web of Science ®Google Scholar
• Dimitriadis G, Gerich J. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983; 6: 374–377
   PubMed Web of Science ®Google Scholar
• Gold A E, MacLeod K M, Frier B M. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994; 17: 697–703
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Ronn B B, Endahl L, Heinemann L, Kapitza C, Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614–1620
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 2006; 29: 1269–1274
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?. Diabetes Obes Metab 2007; 9: 209–217
   PubMed Web of Science ®Google Scholar
• Holleman F, Gale E A. Nice insulins, pity about the evidence. Diabetologia 2007; 50: 1783–1790
   PubMed Web of Science ®Google Scholar
• Holman R R, Thorne K I, Farmer A J, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716–1730
   PubMed Web of Science ®Google Scholar
• Kelley D E. Sugars and starch in the nutritional management of diabetes mellitus. Am J Clin Nutr 2003; 78: 858S–864S
   PubMed Web of Science ®Google Scholar
• Kilpatrick E S, Rigby A S, Atkin S I. The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes. Diabetes Care 2006; 29: 1486–1490
   PubMed Web of Science ®Google Scholar
• Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini M G, Bartocci L, Brunetti P, Bolli G B. Long-term intensive treatment of Type 1 diabetes with the short-acting insulin analogue lispro in variable combination with NPH insulin at meal time. Diabetes Care 1999; 22: 468–477
   PubMed Web of Science ®Google Scholar
• Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli G B. Pharmacokinetics and pharmacodynamics of the long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin injected subcutaneously, and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142–2148
   PubMed Web of Science ®Google Scholar
• Luzio S, Dunseath G, Peter R, Pauvaday V, Owens D R. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 2006; 49: 1163–1168
   PubMed Web of Science ®Google Scholar
• Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881–885
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C, Dunseath G J, Owens D R. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30: 263–269
   PubMed Web of Science ®Google Scholar
• Nathan D M, Buse J B, Davidson M B, Heine R J, Holman R R, Shweriwn R, Zinmann B. Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006; 29: 1963–1972
   PubMed Web of Science ®Google Scholar
• Paulescu N C. Recherche sur le rôle du pancréas dans l'assimilation nutritive. Arch Int Physiol 1921; 17: 85–109
   Google Scholar
• Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. Br Med J 2002; 324: 1–6
   PubMed Web of Science ®Google Scholar
• Pieber T R, Treichel H C, Hompesch B, Philotheou A, Mordhorst L, Gall M A, Robertson L I. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med 2007; 24: 635–642
   PubMed Web of Science ®Google Scholar
• Plank J, Siebenhofer A, Berghold A, Jeitler K, Horvath K, Mrak P, Pieber T R. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005; 165: 1337–1344
   PubMed Web of Science ®Google Scholar
• Porcellati F, Rossetti P, Pampanelli S, Fanelli C G, Torlone E, Scionti L, Perriello G, Bolli G B. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004; 21: 1213–1220
   PubMed Web of Science ®Google Scholar
• Porcellati F, Rossetti P, Fanelli C G, Bolli G B. Optimized use of glargine in intensive treatment of type 1 diabetes mellitus: benefits and a new question. (Abstract) Diabetes 2005; 54(S1)A129
   Google Scholar
• Porcellati F, Rossetti P, Busciantella Ricci N, Pampanelli S, Torlone E, Herdandez Campos S, Marinelli Andreoli A, Bolli G B, Fanelli C G. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after one week of use as compared to its first administration in subjects with Type 1 diabetes mellitus. Diabetes Care 2007a; 30: 1261–1263
   PubMed Web of Science ®Google Scholar
• Porcellati F, Rossetti P, Busciantella S, Marzotti S, Lucidi P, Fanelli C G, Luzio S, Owens D, Bolli G B. Pharmacokinetics and – dynamics of therapeutic doses of the “long-acting” insulin analogs glargine and detemir at steady-state in Type 1 diabetes mellitus. Diabetes Care 2007b; 30: 2447–2452
   PubMed Web of Science ®Google Scholar
• Raskin P, Allen E, Hollander P, Lewin A, Gabbay R A, Hu P, Bode B, Garber A, INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260–265
   PubMed Web of Science ®Google Scholar
• Riddle M C, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080–3086
   PubMed Web of Science ®Google Scholar
• Rossetti P, Porcellati F, Fanelli C G, Bolli G B. Mechanisms and Treatment of the “Afternoon Phenomenon” in Patients with Type 1 Diabetes Mellitus Using Glargine as Basal Insulin. (abstract) Diabetes 2005; 54(S1)A68
   Google Scholar
• Siebenhofer A, Plank J, Berghold A, Horvath K, Sawicki P T, Beck P, Pieber T R. Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy. Diabetologia 2004; 47: 1895–1905
   PubMed Web of Science ®Google Scholar
• Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, Gfrerer R, Pieber T R. Short-acting insulin analogues versus regular human insulin in patients with diabetes mellitus (Review). The Cochrane Database of Systematic Reviews 2006; 2, Art. No. CD003287.pub4. DOI:10.1002/14651858. CD003287.pub4. (update of the version first published in 2004)
   PubMedGoogle Scholar
• Sonnenberg G E, Berger M. Human insulin: much ado about one amino acid?. Diabetologia 1983; 25: 457–459
   PubMed Web of Science ®Google Scholar
• Torlone E, Pampanelli S, Lalli C, Del Sindaco P, Di Vincenzo A, Rambotti A M, Modarelli F, Epifano L, Kassi G, Perriello G, et al. Effects of the short-acting insulin analog [LYS(B28), PRO(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 1996; 19: 945–952
   PubMed Web of Science ®Google Scholar
• Zinman B, Tildesley H, Chiasson J L, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997; 46: 440–443
   PubMed Web of Science ®Google Scholar
• Zisman A, Miller M, Tanenberg R. Relationship between prior mild-moderate hypoglycaemic events and the risk of subsequent severe hypoglycaemia in patients with type 2 diabetes mellitus treated with basal insulin according to fasting BG targets: a time-dependent covariate analysis. Diabetologia 2007; 50(S1)S82
   Google Scholar